Advertisement
Screener

MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities

2.8 / 5 stars · 68/120 Roast Me

MATINAS BIOPHARMA HOLDINGS, INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities

MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $52.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-13

  • MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was -$190.00K.
  • MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was $242.00K.
  • MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was -$115.00K, a 115.01% decline year-over-year.
  • MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$230.00K.
  • MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$1.35M, a 480.06% decline from fiscal 2024.
  • MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $356.00K.
  • MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$1.65M, a 763.05% decline from fiscal 2022.
  • MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $249.00K, a 336.84% increase from fiscal 2021.
Period endIncrease (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 monthIncrease (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month as first filedIncrease (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 monthIncrease (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month as first filedIncrease (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 monthIncrease (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month as first filedIncrease (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 monthIncrease (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month as first filed
2026-06-30-$190.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
$52.00K
10-Q · filed 2026-08-13
-$63.00K
derived: sum of 3 quarters · filed 2026-08-13
-$293.00K
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31$242.00K
10-Q · filed 2026-05-08
$127.00K
derived: sum of 2 quarters · filed 2026-05-08
-$103.00K
derived: sum of 3 quarters · filed 2026-05-08
-$484.00K
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31-$115.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
-$345.00K
derived: sum of 2 quarters · filed 2026-03-31
-$726.00K
derived: sum of 3 quarters · filed 2026-08-13
-$1.35M
10-K · filed 2026-03-31
2025-09-30-$230.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
-$611.00K
derived: sum of 2 quarters · filed 2026-08-13
-$1.24M
10-Q · filed 2025-11-10
-$472.00K
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30-$381.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
-$1.01M
10-Q · filed 2026-08-13
-$242.00K
derived: sum of 3 quarters · filed 2026-08-13
-$646.00K
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31-$627.00K
10-Q · filed 2026-05-08
$139.00K
derived: sum of 2 quarters · filed 2026-05-08
-$265.00K
derived: sum of 3 quarters · filed 2026-05-08
$339.00K
derived: sum of 4 quarters · filed 2026-05-08
2024-12-31$766.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
$362.00K
derived: sum of 2 quarters · filed 2026-03-31
$966.00K
derived: sum of 3 quarters · filed 2026-03-31
$356.00K
10-K · filed 2026-03-31
2024-09-30-$404.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
$200.00K
derived: sum of 2 quarters · filed 2025-11-10
-$410.00K
10-Q · filed 2025-11-10
-$721.00K
derived: sum of 4 quarters · filed 2025-11-10
2024-06-30$604.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
-$6.00K
10-Q · filed 2025-08-14
-$317.00K
derived: sum of 3 quarters · filed 2025-08-14
$69.00K
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31-$610.00K
10-Q · filed 2025-05-15
-$921.00K
derived: sum of 2 quarters · filed 2025-05-15
-$535.00K
derived: sum of 3 quarters · filed 2025-05-15
$44.00K
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31-$311.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15
$75.00K
derived: sum of 2 quarters · filed 2025-04-15
$654.00K
derived: sum of 3 quarters · filed 2025-04-15
-$1.65M
10-K · filed 2025-04-15
2023-09-30$386.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13
$965.00K
derived: sum of 2 quarters · filed 2024-11-13
-$1.34M
10-Q · filed 2024-11-13
-$1.94M
derived: sum of 4 quarters · filed 2024-11-13
2023-06-30$579.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
-$1.73M
10-Q · filed 2024-08-14
-$2.32M
derived: sum of 3 quarters · filed 2024-08-14
-$2.92M
derived: sum of 4 quarters · filed 2024-08-14
2023-03-31-$2.31M
10-Q · filed 2024-05-09
-$2.90M
derived: sum of 2 quarters · filed 2024-05-09
-$3.50M
derived: sum of 3 quarters · filed 2024-05-09
-$1.05M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31-$597.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27
-$1.19M
derived: sum of 2 quarters · filed 2024-03-27
$1.26M
derived: sum of 3 quarters · filed 2024-03-27
$249.00K
10-K · filed 2024-03-27
2022-09-30-$597.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08
$1.86M
derived: sum of 2 quarters · filed 2023-11-08
$846.00K
10-Q · filed 2023-11-08
$846.04K
10-Q · filed 2022-11-02
$804.43K
derived: sum of 4 quarters · filed 2023-11-08
2022-06-30$2.45M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09
$1.44M
10-Q · filed 2023-08-09
$1.44M
10-Q · filed 2022-08-11
$1.40M
derived: sum of 3 quarters · filed 2023-08-09
$1.53M
derived: sum of 4 quarters · filed 2023-08-09
2022-03-31-$1.01M
10-Q · filed 2023-05-10
-$1.01M
10-Q · filed 2022-05-12
-$1.05M
derived: sum of 2 quarters · filed 2023-05-10
-$920.41K
derived: sum of 3 quarters · filed 2023-05-10
$436.58K
derived: sum of 4 quarters · filed 2023-05-10
2021-12-31-$41.57K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15
$89.59K
derived: sum of 2 quarters · filed 2023-03-15
$1.45M
derived: sum of 3 quarters · filed 2023-03-15
$57.00K
10-K · filed 2023-03-15
$55.56K
10-K · filed 2022-03-08
2021-09-30$131.17K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02
$1.49M
derived: sum of 2 quarters · filed 2022-11-02
$98.57K
10-Q · filed 2022-11-02
$813.80K
derived: sum of 4 quarters · filed 2022-11-02
2021-06-30$1.36M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
-$32.59K
10-Q · filed 2022-08-11
$682.63K
derived: sum of 3 quarters · filed 2022-08-11
$1.26M
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31-$1.39M
10-Q · filed 2022-05-12
-$674.36K
derived: sum of 2 quarters · filed 2022-05-12
-$94.14K
derived: sum of 3 quarters · filed 2022-05-12
$224.67K
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31$715.23K
derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-11
$1.30M
derived: sum of 2 quarters · filed 2022-03-11
$1.61M
derived: sum of 3 quarters · filed 2022-03-11
$855.82K
10-K/A · filed 2022-03-11
2020-09-30$580.22K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
$899.03K
derived: sum of 2 quarters · filed 2021-11-08
$140.59K
10-Q · filed 2021-11-08
$607.25K
derived: sum of 4 quarters · filed 2021-11-08
2020-06-30$318.81K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10
-$439.63K
10-Q · filed 2021-08-10
$27.03K
derived: sum of 3 quarters · filed 2021-08-10
$214.84K
derived: sum of 4 quarters · filed 2021-08-10
2020-03-31-$758.44K
10-Q · filed 2021-05-10
-$291.78K
derived: sum of 2 quarters · filed 2021-05-10
-$103.97K
derived: sum of 3 quarters · filed 2021-05-10
$160.40K
derived: sum of 4 quarters · filed 2021-05-10
2019-12-31$466.66K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29
$654.47K
derived: sum of 2 quarters · filed 2021-03-29
$918.84K
derived: sum of 3 quarters · filed 2021-03-29
$842.56K
10-K · filed 2021-03-29
2019-09-30$187.80K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06
$452.18K
derived: sum of 2 quarters · filed 2020-11-06
$375.90K
10-Q · filed 2020-11-06
$704.43K
derived: sum of 4 quarters · filed 2020-11-06
2019-06-30$264.37K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
$188.09K
10-Q · filed 2020-08-10
$516.62K
derived: sum of 3 quarters · filed 2020-08-10
$335.36K
derived: sum of 4 quarters · filed 2020-08-10
2019-03-31-$76.28K
10-Q · filed 2020-05-11
$252.25K
derived: sum of 2 quarters · filed 2020-05-11
$70.99K
derived: sum of 3 quarters · filed 2020-05-11
$548.36K
derived: sum of 4 quarters · filed 2020-05-11
2018-12-31$328.53K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09
$147.27K
derived: sum of 2 quarters · filed 2020-03-09
$624.63K
derived: sum of 3 quarters · filed 2020-03-09
$97.78K
10-K · filed 2020-03-09
2018-09-30-$181.26K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13
$296.11K
derived: sum of 2 quarters · filed 2019-11-13
-$230.74K
10-Q · filed 2019-11-13
2018-06-30$477.37K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13
-$49.48K
10-Q · filed 2019-08-13
2018-03-31-$526.85K
10-Q · filed 2019-05-13
2017-12-31$159.36K
10-K · filed 2019-04-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
Petros Pharmaceuticals, Inc. (PTPI)United States$0.003B
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
GeoVax Labs, Inc. (GOVX)United States$0.003B-0.45
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
Silo Pharma, Inc. (SILO)United States$0.003B-1.57
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
Genprex, Inc. (GNPX)United States$0.003B-0.02
Alaunos Therapeutics, Inc. (TCRT)United States$0.003B-1.44
ORAGENICS INC (OGEN)United States$0.002B
Nexentis Technologies Inc. (NXTS)$0.002B